MANUEL SKOW: Open Payments
NPI 1083888481 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,551 in 118 payments from 27 companies in 2025. Trend: 2023 $2,535 · 2024 $2,308 · 2025 $2,551
Food & beverage: $2,551
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 21 | $498 |
| Lilly USA, LLC | 13 | $274 |
| Dexcom, Inc. | 7 | $213 |
| ABBVIE INC. | 9 | $172 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $159 |
| PFIZER INC. | 9 | $156 |
| AstraZeneca Pharmaceuticals LP | 6 | $128 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $124 |
| Exact Sciences Corporation | 4 | $79 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $78 |
Products named: MOUNJARO, Rybelsus, JARDIANCE, Ozempic, XIFAXAN, Dexcom G6 Transmitter, VRAYLAR, Wegovy.
Industry payments across MD — which companies pay providers there.
